<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764308</url>
  </required_header>
  <id_info>
    <org_study_id>O3FA</org_study_id>
    <nct_id>NCT01764308</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Fatty Acid Supplementation in Acne Patients</brief_title>
  <acronym>Omega-3</acronym>
  <official_title>Omega-3 Fatty Acid Supplementation in Acne Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 patients receiving isotretinoin will be recruited from the UCLA acne specialty clinic.&#xD;
      Subjects will be randomized in a 1:1 ratio to receive placebo or omega-3 1200mg twice a day&#xD;
      for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental Design&#xD;
&#xD;
      60 patients receiving isotretinoin will be recruited from the UCLA acne specialty clinic.&#xD;
      Subjects will be randomized in a 1:1 ratio to receive placebo or omega-3 1200mg twice a day&#xD;
      for 24 weeks.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Male or female above 18 years of age.&#xD;
&#xD;
        -  Moderate to severe disease at the baseline of the study identified by their&#xD;
           dermatologist.&#xD;
&#xD;
        -  Will start treatment with systemic therapy for acne in the form of either isotretinoin&#xD;
           or oral antibiotics.&#xD;
&#xD;
        -  Patients able and willing to comply with the procedures in the study protocol.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Patients with history of taking omega-3 supplements for high triglyceride levels.&#xD;
&#xD;
        -  Patients taking medications for dyslipidemia, blood thinners, or high blood pressure&#xD;
           medication.&#xD;
&#xD;
        -  Patients with a history of adverse reaction to omega-3 fatty acid supplementation.&#xD;
&#xD;
        -  Unwilling to give inform consent&#xD;
&#xD;
      First Visit (Baseline)&#xD;
&#xD;
      All patients will complete an intake survey. This survey will include self-assessment via&#xD;
      Leed's standardized photo scale, and the Skindex 16 quality of life questionnaire.&#xD;
&#xD;
      Physicians will complete acne assessment on all patients. This includes lesion counts,&#xD;
      standardized Leed's photo scale and global assessment scale 0-5.&#xD;
&#xD;
      Fasting blood sample will be obtained for chemistry and lipid panel if being treated with&#xD;
      isotretinoin, as is standard for this therapy.&#xD;
&#xD;
      Follow-up visits at weeks 8, 16, 24:&#xD;
&#xD;
      Patients will come in at weeks 8, 16 and 24 for the following procedures:&#xD;
&#xD;
      All patients will fill out follow-up survey at each visit. The survey will elicit information&#xD;
      regarding compliance with medication, compliance with supplementation, side effects of&#xD;
      supplementation, side effects of acne therapy, and satisfaction with therapy.&#xD;
&#xD;
      Follow-up surveys will include patient self assessment with Leed's photo scale, and Skindex&#xD;
      16 questionnaire.&#xD;
&#xD;
      Physicians will complete acne assessment on all patients. This includes lesion counts, photo&#xD;
      scale and global assessment (Grade 0-5). See attached &quot;Physician checklist.&quot;&#xD;
&#xD;
      Patients will have fasting blood drawn for lipid panel if being treated with isotretinoin, as&#xD;
      is standard for this therapy.&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
      In all study patients being treated for acne, lesion counts will be assessed and evaluated&#xD;
      for any differences between patients on omega-3 fatty acid supplementation and not on&#xD;
      supplementation.&#xD;
&#xD;
      Global assessment, photo scale assessment and Skindex-16 quality of life assessment will be&#xD;
      compared between patients with and without supplementation.&#xD;
&#xD;
      We will compare triglyceride levels in patients being treated with isotretinoin with and&#xD;
      without omega-3 fatty acid supplementation.&#xD;
&#xD;
      Overall satisfaction with therapy will be compared between patients with O3FA supplementation&#xD;
      and without supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient staff to complete recruitment&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acne Lesion Count</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>In all study patients being treated for acne, lesion counts will be assessed and evaluated for any differences between patients on omega-3 fatty acid supplementation and not on supplementation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega 3 Fatty Acid 1200mg twice a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 tablets twice a day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>1200mg twice a day for 24 weeks</description>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Omega-3 fatty acid; fish oil supplement; alpha-linolenic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets twice a day for 24 weeks</description>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female above 18 years of age.&#xD;
&#xD;
          -  Moderate to severe disease at the baseline of the study identified by their&#xD;
             dermatologist.&#xD;
&#xD;
          -  Will start treatment with systemic therapy for acne in the form of either isotretinoin&#xD;
             or oral antibiotics.&#xD;
&#xD;
          -  Patients able and willing to comply with the procedures in the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of taking omega-3 supplements for high triglyceride levels.&#xD;
&#xD;
          -  Patients taking medications for dyslipidemia, blood thinners, or high blood pressure&#xD;
             medication.&#xD;
&#xD;
          -  Patients with a history of adverse reaction to omega-3 fatty acid supplementation.&#xD;
&#xD;
          -  Unwilling to give inform consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina N Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn Goh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA Division of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Califonia, Los Angeles Division of Dermatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaiser Permanente</investigator_affiliation>
    <investigator_full_name>Christina Kim, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>acne; omega-3; isotretinoin; placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

